MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.lanhl.2025.100764

Медицинская библиотека · The lancet. Healthy longevity · 2025

Aspirin and healthy lifespan in older people: main outcome of the ASPREE-XT observational study.

Shah Raj C, Ryan Joanne, Webb Katherine L, Wolfe Rory, Chan Andrew, Chong Trevor T-J, Ernst Michael E, Espinoza Sara E, Flynn Olivia, Lee Song Yuin, McNeil John, Nelson Mark R, Orchard Suzanne G, Reid Christopher M, Sheets Kerry, Stocks Nigel P, Weerasinghe Nilakshi S, Wilson Michelle E, Woods Robyn L, Murray Anne M

СтатьяНаблюдательное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

In the Aspirin in Reducing Events in the Elderly (ASPREE) clinical trial, low-dose aspirin was not associated with survival free of dementia and persistent physical disability (a measure of a healthy lifespan); however, there was a small increased risk of death. Given the long pre-clinical phase of many ageing conditions, we aimed to examine the legacy effect (post-trial) and the longer-term effect of aspirin versus placebo through extended follow-up in the ASPREE-XT observational study.

METHODS

Between March 10, 2010, and Dec 24, 2014, 19 114 community-dwelling people in Australia and the USA, aged predominantly 70 years and older, were randomly assigned to low-dose aspirin or placebo for a median of 4·7 years as part of the ASPREE trial. Post-trial observational follow-up continued for a median of 4·3 years (IQR 4·1-4·6). All components of the primary endpoint (ie, incident dementia, persistent physical disability, and death) were adjudicated by masked expert panels. Analyses used Cox proportional hazards models with intention-to-treat.

FINDINGS: 15 633 participants (8836 [56·5%] were women, 6797 [43·5%] were men; 981 [6·3%] were not White) were eligible for and agreed to observational follow-up. There was no effect of randomisation to aspirin (34·37 events per 1000 person-years) versus placebo (33·68 per 1000 person-years) on the primary endpoint (hazard ratio [HR] 1·02; 95% CI 0·94-1·11; p=0·63) in the ASPREE-XT period. Similarly, over the period of both ASPREE and ASPREE-XT, no long-term effect of aspirin versus placebo was observed on the composite outcome of death, dementia, or persistent physical disability over almost a decade of follow-up (HR 1·01; 95% CI 0·95-1·08; p=0·65), including no long-term effect on deaths (1·06; 0·99-1·14; p=0·10). No effect of aspirin on incident major haemorrhagic events as compared with placebo was found in ASPREE-XT; however, aspirin was associated with an increased hazard for incident major haemorrhagic events across both ASPREE and ASPREE-XT (1·24; 1·10-1·39).

INTERPRETATION: Low-dose aspirin does not appear to be effective in promoting a healthy lifespan in initially healthy, community-dwelling older people.

FUNDING: National Institute on Aging and the National Cancer Institute (USA).

Для цитирования: Shah Raj C, Ryan Joanne, Webb Katherine L, Wolfe Rory, Chan Andrew, Chong Trevor T-J, Ernst Michael E, Espinoza Sara E, Flynn Olivia, Lee Song Yuin, McNeil John, Nelson Mark R, Orchard Suzanne G, Reid Christopher M, Sheets Kerry, Stocks Nigel P, Weerasinghe Nilakshi S, Wilson Michelle E, Woods Robyn L, Murray Anne M. Aspirin and healthy lifespan in older people: main outcome of the ASPREE-XT observational study.. The lancet. Healthy longevity. 2025. DOI: 10.1016/j.lanhl.2025.100764.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.